Clinical Trials

Phase 2 Not yet recruiting

Pancreatic Ductal Adenocarcinoma

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Locally Advanced Rectal Cancer

NCT02386397 2026-03-12

BREGO

Phase 1/2 Completed

66 enrolled

Gastrointestinal Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Phase EARLY_PHASE1 Active not recruiting

Colonic Neoplasms

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

2 enrolled

Phase 2 Not yet recruiting

Colonic Neoplasms

NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

80 enrolled

Gastric Adenocarcinoma

NCT01918527 2026-03-10

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

250 enrolled

Colonic Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

100 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06269978 2026-03-10

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

Phase 1 Recruiting

24 enrolled

Colorectal Neoplasms

NCT06780111 2026-03-10

MK-3475-06E

Phase 1/2 Recruiting

298 enrolled

Phase 2/3 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07462143 2026-03-10

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

700 enrolled

Colonic Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

770 enrolled 13 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04083235 2026-03-09

NAPOLI 3

Phase 3 Completed

Metastatic Adenocarcinoma of the Pancreas

NCT06764875 2026-03-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Phase 2 Completed

46 enrolled 15 charts

GastrointestinalGynecologic

Pancreatic Neoplasms

NCT04847063 2026-03-06

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

Phase 1 Recruiting

60 enrolled

Appendiceal Neoplasms, Gastrointestinal Neoplasms, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07070466 2026-03-06

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

40 enrolled

Phase 1/2 Not yet recruiting

Esophageal Neoplasms, Stomach Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04230187 2026-03-05

TRIBE-C

528 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

50 enrolled

Phase 2 Active not recruiting

Rectal Neoplasms

NCT04757363 2026-03-04

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

39 enrolled

Esophageal Neoplasms

NCT05568095 2026-03-04

STAR-221

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

382 enrolled

Phase 1/2 Active not recruiting

Adenocarcinoma Of Esophagus

NCT05846867 2026-03-04

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

170 enrolled

Colorectal Neoplasms

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

560 enrolled

Colorectal Adenocarcinoma

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Rectal Neoplasms

NCT06461910 2026-03-03

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

30 enrolled

Stomach Neoplasms

NCT06787183 2026-03-03

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

42 enrolled

Locally Advanced Rectal Cancer With Liver Metastases

NCT07228832 2026-03-03

HARMONi-GI3

600 enrolled

Phase 4 Not yet recruiting

Colorectal Neoplasms

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

42 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT04248452 2026-03-02

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

314 enrolled

Adenocarcinoma Of Esophagus

NCT05863195 2026-03-02

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

408 enrolled